| 5.1 Symptomatic DVT: DOAC vs placebo |
3 |
1526 |
Risk Ratio (IV, Random, 95% CI) |
0.51 [0.21, 1.22] |
| 5.1.1 Apixaban |
2 |
685 |
Risk Ratio (IV, Random, 95% CI) |
0.27 [0.04, 1.73] |
| 5.1.2 Rivaroxaban |
1 |
841 |
Risk Ratio (IV, Random, 95% CI) |
0.79 [0.41, 1.54] |
| 5.2 Symptomatic DVT: LMWH vs no thromboprophylaxis |
9 |
5408 |
Risk Ratio (IV, Random, 95% CI) |
0.48 [0.35, 0.67] |
| 5.2.1 Dalteparin |
6 |
3063 |
Risk Ratio (IV, Random, 95% CI) |
0.50 [0.32, 0.77] |
| 5.2.2 Nadroparin |
1 |
1150 |
Risk Ratio (IV, Random, 95% CI) |
0.50 [0.19, 1.31] |
| 5.2.3 Certoparin |
1 |
883 |
Risk Ratio (IV, Random, 95% CI) |
0.46 [0.18, 1.20] |
| 5.2.4 Enoxaparin |
1 |
312 |
Risk Ratio (IV, Random, 95% CI) |
0.45 [0.22, 0.93] |
| 5.3 Symptomatic DVT: prophylactic vs intermediate or therapeutic LMWH |
1 |
|
Risk Ratio (IV, Fixed, 95% CI) |
Subtotals only |
| 5.3.1 Prophylactic vs intermediate |
1 |
51 |
Risk Ratio (IV, Fixed, 95% CI) |
Not estimable |
| 5.3.2 Prophylactic vs therapeutic |
1 |
52 |
Risk Ratio (IV, Fixed, 95% CI) |
0.33 [0.01, 7.82] |
| 5.4 Symptomatic DVT: LMWH vs aspirin |
2 |
781 |
Risk Ratio (IV, Random, 95% CI) |
0.81 [0.32, 2.04] |
| 5.5 Symptomatic DVT: LMWH vs warfarin |
1 |
439 |
Risk Ratio (IV, Fixed, 95% CI) |
0.43 [0.17, 1.10] |
| 5.6 Symptomatic DVT: semuloparin vs placebo |
1 |
3212 |
Risk Ratio (IV, Fixed, 95% CI) |
0.32 [0.16, 0.63] |
| 5.7 Symptomatic DVT: vitamin K antagonists vs placebo |
1 |
311 |
Risk Ratio (IV, Fixed, 95% CI) |
0.08 [0.00, 1.42] |
| 5.8 Symptomatic DVT: warfarin vs aspirin |
1 |
440 |
Risk Ratio (IV, Fixed, 95% CI) |
1.75 [0.75, 4.09] |
